Global Supplies Management
Vaccine trials require accurate drug supply forecasting and a dynamic supply chain to support sites in regions where virus prevalence changes quickly. That's why companies such as AstraZeneca save 10%+ annually from their drug supply budget by transforming forecasting and supply chain efficiency with Signant.
Efficient Patient Data Capture
With hundreds or thousands of participants reporting symptoms for 7-14 days after vaccine intervention, trust SmartSignals eCOA and our built-in reactogenicity diary to capture accurate, time-stamped data. Receive real-time alerts of potential adverse event indicators, and eliminate the costly transcription errors and delays inherent with paper.
Compliance and Retention
Participants in vaccine trials must understand complex information and risks involved with your vaccine study. That's why we offer eConsent and Patient Concierge solutions alongside eCOA. This ensures patients fully understand their study commitment and keeps your trial top of mind to support adherence and completion.
WHEN PFIZER NEEDED eCOA ASAP, WE ANSWERED THE CALL
VACCINE TRIALS
Solutions to address clinical & operational challenges
When the world is counting on you -
count on Signant
Whether you’re developing new vaccines for COVID-19, RSV, CMV, chickengunya, Lyme’s disease, or hantavirus, count on Signant to help you generate high quality evidence for submission.
40,000 PATIENTS
6
COUNTRIES
17
LANGUAGES
5
WEEKS
163
SITES
RELIABLE SAFETY & EFFICACY DATA, PLUS SO MUCH MORE
We know vaccine studies are often large and globally dispersed with sensitive timeframes, extended participant follow-up periods, multiphase designs, and critical data management needs. Leverage SmartSignals to navigate these challenges and gather the audit-ready, high quality evidence you need to get your vaccine to the public.
